Cargando…

Targeting IAP proteins in combination with radiotherapy

The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells a...

Descripción completa

Detalles Bibliográficos
Autor principal: Fulda, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436972/
https://www.ncbi.nlm.nih.gov/pubmed/25927408
http://dx.doi.org/10.1186/s13014-015-0399-3
_version_ 1782372163135733760
author Fulda, Simone
author_facet Fulda, Simone
author_sort Fulda, Simone
collection PubMed
description The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells are required in order to overcome resistance to radiotherapy. Since Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in multiple cancers and block cell death induction at a central point, therapeutic targeting of IAP proteins represents a promising approach to potentiate the efficacy of radiotherapy. The current review discusses the concept of targeting IAP proteins in combination with radiotherapy.
format Online
Article
Text
id pubmed-4436972
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44369722015-05-20 Targeting IAP proteins in combination with radiotherapy Fulda, Simone Radiat Oncol Review The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells are required in order to overcome resistance to radiotherapy. Since Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in multiple cancers and block cell death induction at a central point, therapeutic targeting of IAP proteins represents a promising approach to potentiate the efficacy of radiotherapy. The current review discusses the concept of targeting IAP proteins in combination with radiotherapy. BioMed Central 2015-04-26 /pmc/articles/PMC4436972/ /pubmed/25927408 http://dx.doi.org/10.1186/s13014-015-0399-3 Text en © Fulda; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Fulda, Simone
Targeting IAP proteins in combination with radiotherapy
title Targeting IAP proteins in combination with radiotherapy
title_full Targeting IAP proteins in combination with radiotherapy
title_fullStr Targeting IAP proteins in combination with radiotherapy
title_full_unstemmed Targeting IAP proteins in combination with radiotherapy
title_short Targeting IAP proteins in combination with radiotherapy
title_sort targeting iap proteins in combination with radiotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436972/
https://www.ncbi.nlm.nih.gov/pubmed/25927408
http://dx.doi.org/10.1186/s13014-015-0399-3
work_keys_str_mv AT fuldasimone targetingiapproteinsincombinationwithradiotherapy